Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AMPE Stock Summary
In the News
Ampio Pharmaceuticals to Present at the Emerging Growth Conference
ENGLEWOOD, Colo. , Sept. 26, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") a pre-revenue stage biopharmaceutical Company focused on development of a potential treatment for osteoarthritis as part of its OA.201 program, today announced that its CEO, Michael A.
3 Biotech Stocks to Buy With Explosive Upside Potential
The biotech sector will always house stocks with explosive upside potential. The very nature of the sector ensures that will continue to be the case.
Which Strategies Are You Using With Penny Stocks in September?
Are you using these strategies for trading penny stocks right now? The post Which Strategies Are You Using With Penny Stocks in September?
Why These 3 Penny Stocks Are Climbing in Late April
Are these three penny stocks on your watchlist right now? The post Why These 3 Penny Stocks Are Climbing in Late April appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Ampio Pharma Shares Fall As FDA Rejects Proposed Change In Knee Osteoarthritis Trial
Ampio Pharmaceuticals Inc (NYSE: AMPE) received written responses from the FDA pursuant to a Type C meeting request regarding the AP-013 Phase 3 trial results. In March, Ampio announced data from the modified Intent-To-Treat (mITT) population (n=618) in the AP-013 study of Ampion in.
New Strong Sell Stocks for April 7th
AMPE, ANIK, and FAT have been added to the Zacks Rank #5 (Strong Sell) List on April 7, 2022.
New Strong Sell Stocks for April 1st
AKYA, AMPE, and BITF have been added to the Zacks Rank #5 (Strong Sell) List on April 1, 2022.
Ampio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call Transcript
Ampio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call Transcript
Why Ampio Pharmaceuticals Stock Is Rising Today
Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading significantly higher Thursday following bullish analyst coverage. Alliance Global Partners analyst James Molloy initiated coverage on Ampio Pharmaceuticals with a Buy rating and announced a $4.50 price target, which is well.
Ampio (AMPE) Upgraded to Buy: Here's What You Should Know
Ampio (AMPE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AMPE Financial details
AMPE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 88.39 | -18.32 | -28.63 | -18.79 | -11.24 | |
Operating cash flow per share | -31.57 | -32.45 | -25.56 | -21.21 | -28.04 | |
Free cash flow per share | -33.04 | -32.5 | -25.67 | -21.35 | -28.04 | |
Cash per share | 19.73 | 13.78 | 30.11 | 51.02 | 16.79 | |
Book value per share | 13.62 | 13.59 | 30.39 | 41.07 | 15.64 | |
Tangible book value per share | 13.62 | 13.59 | 30.39 | 41.07 | 15.64 | |
Share holders equity per share | 13.62 | 13.59 | 30.39 | 41.07 | 15.64 | |
Interest debt per share | -0.01 | 3.26 | 2.1 | 1.39 | -9.63 | |
Market cap | 44.98M | 82.48M | 274.83M | 113.6M | 3.47M | |
Enterprise value | 37.4M | 77.42M | 258.69M | 80.63M | -8.57M | |
P/E ratio | 1.32 | -9.5 | -16.66 | -9.1 | -0.41 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -3.71 | -5.36 | -18.66 | -8.06 | -0.16 | |
PFCF ratio | -3.54 | -5.35 | -18.58 | -8.01 | -0.16 | |
P/B Ratio | 8.59 | 12.8 | 15.69 | 4.16 | 0.29 | |
PTB ratio | 8.59 | 12.8 | 15.69 | 4.16 | 0.29 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -0.68 | -3.49 | -18.42 | -3.35 | 0.37 | |
EV to operating cash flow | -3.08 | -5.03 | -17.56 | -5.72 | 0.41 | |
EV to free cash flow | -2.94 | -5.03 | -17.49 | -5.68 | 0.41 | |
Earnings yield | 0.76 | -0.11 | -0.06 | -0.11 | -2.44 | |
Free cash flow yield | -0.28 | -0.19 | -0.05 | -0.12 | -6.09 | |
Debt to equity | 0 | 0.23 | 0.07 | 0.03 | 0.05 | |
Debt to assets | 0 | 0.1 | 0.05 | 0.02 | 0.05 | |
Net debt to EBITDA | 0.14 | 0.23 | 1.15 | 1.37 | 0.52 | |
Current ratio | 5.78 | 1.93 | 10.08 | 6.96 | 11.18 | |
Interest coverage | 2.23K | -304.48 | 0 | 0 | 3.08 | |
Income quality | -0.36 | 1.13 | 0.93 | 0.83 | 1.29 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.05 | 0 | 0 | 0.01 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.44 | -0.02 | -0.05 | -0.09 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 164.58 | 74.85 | 139.94 | 131.78 | 62.88 | |
ROIC | 0.7 | -1.59 | -0.79 | -0.63 | -0.96 | |
Return on tangible assets | 2.42 | -0.62 | -0.72 | -0.32 | -0.62 | |
Graham Net | -3.14 | -2.16 | 21.27 | 34.56 | 14.4 | |
Working capital | 6.61M | 3.97M | 16.66M | 30.51M | 12.14M | |
Tangible asset value | 5.24M | 6.44M | 17.51M | 27.28M | 11.79M | |
Net current asset value | -795.34K | 692K | 13.13M | 24.09M | 11.53M | |
Invested capital | 0 | 0.23 | 0.07 | 0.03 | 0.05 | |
Average receivables | 0 | 0 | 92.5K | 100.5K | 8K | |
Average payables | 0 | 75.5K | 168.5K | 306.5K | 262K | |
Average inventory | 0 | 0 | 133K | 728.5K | 595.5K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 43.33 | 57.63 | 142.46 | 17.03 | |
Days of inventory on hand | 0 | 0 | 82.42 | 397.36 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 8.42 | 6.33 | 2.56 | 21.43 | |
Inventory turnover | 0 | 0 | 4.43 | 0.92 | 0 | |
ROE | 6.49 | -1.35 | -0.94 | -0.46 | -0.72 | |
Capex per share | -1.47 | -0.05 | -0.11 | -0.15 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -8.61 | -2.79 | -4.87 | -1.82 | -1.53 | |
Operating cash flow per share | -7.89 | -5.7 | -3.05 | -4.5 | -0.69 | |
Free cash flow per share | -7.89 | -5.7 | -3.05 | -4.5 | -0.69 | |
Cash per share | 22.49 | 16.79 | 13.72 | 9.21 | 7.96 | |
Book value per share | 18.38 | 15.64 | 10.44 | 8.69 | 6.68 | |
Tangible book value per share | 18.38 | 15.64 | 10.44 | 8.69 | 6.68 | |
Share holders equity per share | 18.38 | 15.64 | 10.44 | 8.69 | 6.68 | |
Interest debt per share | 1.03 | 0.66 | 0.3 | 0.59 | 0.45 | |
Market cap | 13.57M | 3.47M | 3.47M | 3.47M | 2.93M | |
Enterprise value | -2.69M | -8.57M | -6.35M | -3.03M | -3.11M | |
P/E ratio | -0.52 | -0.41 | -0.24 | -0.63 | -0.6 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -2.28 | -0.81 | -1.51 | -1.02 | -5.27 | |
PFCF ratio | -2.28 | -0.81 | -1.51 | -1.02 | -5.27 | |
P/B Ratio | 0.98 | 0.29 | 0.44 | 0.53 | 0.54 | |
PTB ratio | 0.98 | 0.29 | 0.44 | 0.53 | 0.54 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0.58 | 2.96 | 1.53 | 1.94 | 2.22 | |
EV to operating cash flow | 0.45 | 2 | 2.76 | 0.89 | 5.6 | |
EV to free cash flow | 0.45 | 2 | 2.76 | 0.89 | 5.6 | |
Earnings yield | -0.48 | -0.61 | -1.06 | -0.39 | -0.42 | |
Free cash flow yield | -0.44 | -1.24 | -0.66 | -0.98 | -0.19 | |
Debt to equity | 0.05 | 0.05 | 0.07 | 0.07 | 0.07 | |
Debt to assets | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | |
Net debt to EBITDA | 3.53 | 4.16 | 2.36 | 4.17 | 4.31 | |
Current ratio | 4.67 | 11.18 | 4.02 | 3.67 | 3.37 | |
Interest coverage | -61.91 | 26.77 | 14.13 | 0 | 0 | |
Income quality | 0.93 | 1.93 | 0.58 | 2.48 | 0.45 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 59.68 | 31.35 | 33.82 | 18.85 | 15.16 | |
ROIC | -0.33 | -0.22 | -0.44 | -0.2 | -0.22 | |
Return on tangible assets | -0.34 | -0.15 | -0.34 | -0.15 | -0.16 | |
Graham Net | 15.87 | 14.4 | 9.93 | 7.67 | 6.05 | |
Working capital | 14.4M | 12.14M | 8.06M | 6.65M | 5.38M | |
Tangible asset value | 13.85M | 11.79M | 7.88M | 6.56M | 5.38M | |
Net current asset value | 13.33M | 11.53M | 7.88M | 6.56M | 5.38M | |
Invested capital | 0.05 | 0.05 | 0.07 | 0.07 | 0.07 | |
Average receivables | 0 | 0 | 0 | 690K | 955K | |
Average payables | 468K | 157.5K | 336K | 601K | 543K | |
Average inventory | 0 | 0 | 0 | 389K | 732.5K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 28.6 | 23.66 | 211.22 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 3.15 | 3.8 | 0.43 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.47 | -0.18 | -0.47 | -0.21 | -0.23 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
AMPE Frequently Asked Questions
What is Ampio Pharmaceuticals, Inc. stock symbol ?
Ampio Pharmaceuticals, Inc. is a US stock , located in Englewood of Co and trading under the symbol AMPE
What is Ampio Pharmaceuticals, Inc. stock quote today ?
Ampio Pharmaceuticals, Inc. stock price is $0.9 today.
Is Ampio Pharmaceuticals, Inc. stock public?
Yes, Ampio Pharmaceuticals, Inc. is a publicly traded company.